United States · Platforms & data · Finviz

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Published by Finviz · United States 3 d ago

PALO ALTO, Calif., Oct. 16, 2026 (GLOBE NEWSWIRE)-- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing…

Read the full article on Finviz Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (finviz.com)

Also worth reading

The Motley Fool

Better Retail Stock for 2026: GameStop vs. MercadoLibre

Seeking Alpha

Cleveland-Cliffs projects $715M Q4 adjusted EBITDA and outlines path to more than $4B in 2027

MarketWatch

One of this year’s most important relationships in global financial markets is falling apart

CNBC

Anthropic is AI trade's last big hope for a major IPO this year

Investing.com

Cadence Design Systems stock may move 6.2% on earnings

Benzinga